Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 6

See more details

Referenced in 11 patents
26 readers on Mendeley
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI114425

Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein.

P Valet, M Berlan, M Beauville, F Crampes, J L Montastruc, and M Lafontan

Institut de Physiologie, Institut National de la Santé et de la Recherche Medicale, Université Paul Sabatier, Toulouse, France.

Find articles by Valet, P. in: JCI | PubMed | Google Scholar

Institut de Physiologie, Institut National de la Santé et de la Recherche Medicale, Université Paul Sabatier, Toulouse, France.

Find articles by Berlan, M. in: JCI | PubMed | Google Scholar

Institut de Physiologie, Institut National de la Santé et de la Recherche Medicale, Université Paul Sabatier, Toulouse, France.

Find articles by Beauville, M. in: JCI | PubMed | Google Scholar

Institut de Physiologie, Institut National de la Santé et de la Recherche Medicale, Université Paul Sabatier, Toulouse, France.

Find articles by Crampes, F. in: JCI | PubMed | Google Scholar

Institut de Physiologie, Institut National de la Santé et de la Recherche Medicale, Université Paul Sabatier, Toulouse, France.

Find articles by Montastruc, J. in: JCI | PubMed | Google Scholar

Institut de Physiologie, Institut National de la Santé et de la Recherche Medicale, Université Paul Sabatier, Toulouse, France.

Find articles by Lafontan, M. in: JCI | PubMed | Google Scholar

Published January 1, 1990 - More info

Published in Volume 85, Issue 1 on January 1, 1990
J Clin Invest. 1990;85(1):291–295. https://doi.org/10.1172/JCI114425.
© 1990 The American Society for Clinical Investigation
Published January 1, 1990 - Version history
View PDF
Abstract

Neuropeptide Y (NPY) and peptide YY (PYY) are regulatory peptides that have considerable sequence homology with pancreatic polypeptide. Because (a) NPY has been shown to be colocalized with noradrenaline in peripheral as well as central catecholaminergic neurons, and (b) alpha 2-adrenergic receptors of adipocytes play a major role in the regulation of lipolysis, we investigated the effect of NPY and PYY on isolated fat cells. In human fat cells NPY and PYY promoted a dose-dependent inhibition of lipolysis elicited by 2 micrograms/ml adenosine deaminase (removal of adenosine) whatever the lipolytic index used (glycerol or nonesterified fatty acids). In dog fat cells NPY and PYY inhibited adenosine deaminase-, isoproterenol- and forskolin-induced lipolysis. In humans and dogs the effects of NPY or PYY were abolished by treatment of cells with Bordetella pertussis toxin, clearly indicating the involvement of a Gi protein in the antilipolytic effects. This study indicates that, in addition to alpha 2-adrenergic agonists, NPY and PYY are also involved in the regulation of lipolysis in human and dog adipose tissue as powerful antilipolytic agents. Further studies are needed to characterize the pharmacological nature of the receptor mediating the inhibitory effect of NPY and PYY in fat cells.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 291
page 291
icon of scanned page 292
page 292
icon of scanned page 293
page 293
icon of scanned page 294
page 294
icon of scanned page 295
page 295
Version history
  • Version 1 (January 1, 1990): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 6
  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 11 patents
26 readers on Mendeley
See more details